Strs Ohio Nektar Therapeutics Transaction History

Strs Ohio

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 Aug 02, 2023	BUY	$0.64 - $3.15 $36,288 - $178,605	56,700 New	56,700 $39,000
Q2 2022 Jul 25, 2022	BUY	$3.17 - $6.17 $179,739 - $349,839	56,700 New	56,700 $215,000
Q4 2020 Jan 25, 2021	SELL	$15.77 - $19.03 $35,498 - $42,836	-2,251 Closed	0 $0
Q2 2019 Jul 25, 2019	SELL	$31.0 - $36.3 $381,331 - $446,526	-12,301 Reduced 84.53%	2,251 $80,000
Q1 2019 Apr 19, 2019	BUY	$31.58 - $46.35 $78,255 - $114,855	2,478 Added 20.52%	14,552 $488,000
Q4 2018 Jan 23, 2019	SELL	$30.43 - $56.65 $520,383 - $968,771	-17,101 Reduced 58.62%	12,074 $396,000
Q3 2018 Oct 19, 2018	BUY	$46.46 - $68.49 $301,339 - $444,226	6,486 Added 28.59%	29,175 $1.78 Million
Q2 2018 Aug 06, 2018	SELL	$46.25 - $104.45 $648,008 - $1.46 Million	-14,011 Reduced 38.18%	22,689 $1.11 Million
Q1 2018 Apr 20, 2018	BUY	$57.4 - $108.44 $298,480 - $563,888	5,200 Added 16.51%	36,700 $3.9 Million
Q4 2017 Jan 23, 2018	BUY	$23.02 - $60.5 $347,602 - $913,550	15,100 Added 92.07%	31,500 $1.88 Million
Q3 2017 Oct 23, 2017	BUY	$17.79 - $24.0 $291,756 - $393,600	16,400	16,400 $393,000

152

130M

92.7K

4.9K

Ticker NKTR
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 187,404,992
Market Cap $161M
Description
Nektar Therapeutics, a biopharmaceutical company, focuses on discovering and developing medicines in areas of unmet medical need in the United States and internationally. The company's products include Bempegaldesleukin, a CD122-preferential interleukin-2 (IL-2) pathway agonist, which is in phase 3 clinical trial to treat metastatic melanoma, re...

Get notified when there are updates to the investment portfolio of Strs Ohio, based on Form 13F filings with the SEC.

Stay updated on Strs Ohio with notifications on news.